Open AccessSerum Fibroblast Growth Factor-21 Levels Are Associated With Carotid Atherosclerosis Independent of Established Cardiovascular Risk Factors
Author(s) -
Wing Chow,
Aimin Xu,
Yu Cho Woo,
Annette W.K. Tso,
S. Cheung,
Carol Ho-Yan Fong,
HungFat Tse,
Ming Tak Chau,
Bernard M.Y. Cheung,
Karen S.L. Lam
Publication year - 2013
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.113.301599
Subject(s) - medicine , fgf21 , endocrinology , risk factor , diabetes mellitus , dyslipidemia , fibroblast growth factor 23 , creatinine , waist , metabolic syndrome , type 2 diabetes , cohort , obesity , fibroblast growth factor , parathyroid hormone , receptor , calcium
Serum levels of fibroblast growth factor-21 (FGF21), a metabolic hormone, have been shown to be elevated in subjects with adverse lipid profiles, obesity, metabolic syndrome, impaired glucose tolerance, type 2 diabetes mellitus, and hypertension. Recently, elevated serum FGF21 levels have also been reported in subjects with coronary heart disease or carotid artery plaques. However, whether serum FGF21 is independently associated with atherosclerotic diseases remains unclear. In this study, we examined the relationship between serum FGF21 levels and carotid intima-media thickness (IMT) in a large cohort of Southern Chinese subjects.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom